ABVC BioPharma Reports Significant Financial Improvements and Explores AI-Enabled Agricultural Facility in Taiwan

ABVC BioPharma, Inc. reported substantial financial improvements for the first quarter ended March 31, 2025, with operating expenses decreasing 76% to $693,005 compared to $2.84 million in the same period last year. The company's net loss reduced by 68% to $944,190 from $2.93 million in Q1 2024, while basic and diluted net loss per share improved to $(0.06) from $(0.29). These financial results demonstrate the company's progress in optimizing its operations while advancing its clinical development programs.

Concurrently, ABVC recognized a land asset in central Taiwan valued at $7,670,000 and is evaluating the development of a Good Agricultural Practices (GAP)-compliant, AI-powered plant factory at this site. This strategic initiative aligns with the company's long-term vision to enhance vertical integration, improve material consistency, and support its future botanical drug pipeline. The potential facility could leverage local AI capabilities to enable precision-controlled agriculture and contribute to a more sustainable and traceable botanical supply chain, though the company emphasizes there can be no assurance the project will be implemented as currently envisioned.

Dr. Uttam Patil, CEO of ABVC BioPharma, stated that this potential AI-driven agricultural project reflects the company's forward-looking approach to sustainable pharmaceutical innovation. As ABVC continues to advance its clinical pipeline, it is taking steps to evaluate infrastructure that could support long-term scalability. The company emphasized that the land recognition follows applicable accounting standards and responds to prior disclosures related to asset valuation methodology detailed in their 2024 Form 10-K filing with the Securities and Exchange Commission, available at http://www.sec.gov.

ABVC remains committed to executing its clinical development programs while evaluating strategic infrastructure opportunities to support long-term commercialization and partnership growth. The company maintains an active pipeline of six drugs and one medical device under development, utilizing technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For more information about ABVC and its subsidiaries, additional details can be found at https://abvcpharma.com and https://biolite-japan.com.